No description available.

Une cellule dendritique (CD) qui exprime le facteur de transcription GILZ durant l'apprêtement de l'antigène et sa présentation aux cellules effectrices, génère des lymphocytes T régulateurs (LTregs) CD25high Foxp3+ sécréteurs d'IL-10. La production de GILZ est dépendante de l'action des glucocorticoïdes, de l'IL-10 et du TGF-.Nous avons mis en évidence chez l'homme qu'une corticothérapie orale de 48h induit l'expression de GILZ dans les cellules présentatrices de l'antigène circulantes (CPAs) de sujets allergiques. Les CPAs isolées après la corticothérapie génèrent des LTregs CD25high Foxp3+ IL-10+ spécifiques de l'allergène.Nous également constaté in vitro que les mastocytes participent à l'activation des CDs au cours des réactions allergiques en régulant l'expression de GILZ. Les médiateurs d'origine mastocytaire, dont l'histamine, diminuent l'expression de GILZ dans les CDs et altèrent ainsi leur capacité à activer des LTregs. Nous avons identifié le mécanisme par lequel l'histamine diminue l'expression de GILZ dans les CDs humaines. L'histamine inhibe l'activité transcriptionnelle de Foxo3, un facteur de transcription régulant l'expression de GILZ. Enfin, nous avons démontré que des souris transgéniques qui surexpriment GILZ constitutivement dans les CDs sont protégées contre le développement de l'asthme allergique. L'ensemble de ces résultats permet d'envisager de nouvelles stratégies d'immunomodulation dans l'allergie, centrée sur la régulation de l'expression de GILZ dans les CDs.

Les protéines GILZ (Glucocorticoid-Induced Leucine Zipper) et TSC-22 (Transforming growth factor-beta Stimulated Clone-22) appartiennent à la famille de protéines TSC-22D (TSC-22 Domain). GILZ a été décrit précédemment comme étant induit au cours de la déprivation en interleukine-2 (IL-2) des lymphocytes de la lignée cellulaire CTLL-2, permettant ainsi de retarder leur apoptose. Le but de notre travail était de déterminer les rôles respectifs de GILZ et TSC-22 au cours de l'apoptose des cellules CTLL-2.Nos résultats ont permis de montrer que TSC-22 augmentait l'apoptose induite par la déprivation en IL-2 des cellules CTLL-2. Nous avons mis en évidence une augmentation de l'activation des caspases ainsi qu'une régulation positive de l'expression de BIM. Nous avons en outre montré que l'expression de GILZ, protéine anti-apoptotique, induite lors de la déprivation en IL-2, était régulée négativement en présence de TSC-22. Enfin, nous avons montré que l'expression de l'ARNm de gilz était régulée négativement par TSC-22, mais que la stabilité de son ARNm n'était pas modifiée.Notre travail a donc permis de montrer que TSC-22 accélère l'entrée en apoptose des lymphocytes T en régulant négativement l'expression de la protéine anti-apoptotique GILZ.

Les neutrophiles sont généralement considérés résistants aux glucocorticoïdes. Cependant, peu d’études comparant l’effet de ces drogues sur les neutrophiles et les autres leucocytes sanguins (monocytes, lymphocytes et éosinophiles) ont été rapportées. Dans notre étude, nous avons évalué la réponse aux glucocorticoïdes de ces deux populations cellulaires chez le cheval et l’homme. Les cellules, préalablement isolées du sang de 6 chevaux et 4 sujets humains sains, ont été incubées pendant 5 h en présence de lipopolysaccharide (LPS; 100 ng/mL) seul ou combiné avec de l’hydrocortisone, de la prednisolone ou de la dexaméthasone (10-8M et 10-6M). L’expression d’ARNm pour l’IL-1β, le TNF-α, l’IL-8, la glutamine synthétase et le récepteur α des glucocorticoïdes (GR-α) a été quantifiée par qPCR. Les neutrophiles équins ont également été incubés pendant 20 h en présence de ces 3 glucocorticoïdes et la survie cellulaire a été évaluée par cytométrie de flux et microscopie optique. Nous avons démontré que les glucocorticoïdes inhibaient l’expression des gènes pro-inflammatoires induite par le LPS pour les deux populations cellulaires chez les deux espèces étudiées. L’expression de la glutamine synthétase était également significativement augmentée par les glucocorticoïdes chez les neutrophiles et les autres leucocytes sanguins équins. De manière générale, l’intensité de la réponse aux glucocorticoïdes s’est avérée similaire dans les 2 populations leucocytaires et chez les deux espèces. Les glucocorticoïdes augmentaient également la survie des neutrophiles équins, phénomène également rapporté dans d’autres espèces. Ainsi, les glucococorticoïdes exercent des effets d’intensité comparable sur les neutrophiles et les autres leucocytes sanguins. Nous spéculons que la faible réponse à la corticothérapie observée lors de maladies inflammatoires chroniques neutrophiliques comme l’asthme sévère ou la Maladie Pulmonaire Obstructive Chronique (MPOC) ne s’explique pas par une corticorésistance intrinsèque des neutrophiles. / Neutrophils are generally considered resistant to glucocorticoids compared to other inflammatory cells. However, there are few studies comparing the effects of glucocorticoids in neutrophils and those of other blood leukocytes (monocytes, lymphocytes and eosinophils). In our study, we assessed glucocorticoid-responsiveness in equine and human peripheral blood neutrophils and in neutrophil-depleted leukocytes. Cells were isolated from 6 healthy horses and 4 human healthy subjects. They were incubated for 5 h with or without lipopolysaccharide (LPS; 100 ng/mL) alone or combined with hydrocortisone, prednisolone or dexamethasone (10-8M and 10-6M). IL-1β, TNF-α, IL-8, glutamine synthetase and Glucocorticoid Receptor α (GR-α) mRNA expression was quantified by qPCR. Equine neutrophils were also incubated for 20 h with or without the three glucocorticoids and cell survival was assessed by flow cytometry and light microscopy. We found that glucocorticoids down-regulated LPS-induced pro-inflammatory mRNA expression in both cell populations and species. These drugs also significantly increased glutamine synthetase gene expression in both equine cell populations. The magnitude of glucocorticoid response was generally similar in both cell populations and species. As reported in other species, glucocorticoids significantly increase the survival in equine neutrophils. Based on these results, it appears that glucocorticoids exert effects of similar magnitude on neutrophils and on other blood leukocytes. We speculate that the poor response to glucocorticoids observed in some chronic neutrophilic human diseases such as severe asthma or Chronic Obstructive Pulmonary Disease (COPD) is not explained by an inherent attenuated response of neutrophils to these drugs.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Organophosphorus compounds such as methyl-parathion are used in the various stages of production to control pests both in agricultural activity as in aquaculture. The mechanism of action of this type of compound is the inhibition of the enzyme acetylcholinesterase. The zebrafish (Danio rerio) has been increasingly used as an experimental model in varied fields such as development, genetics and pharmacological research. The methyl-parathion has been characterized as endocrine disruptor of the hypothalamic-pituitary-interrenal axis (HHI). An experiment was carried out of 96 hours of exposure of adult fish to the substance tested, at the concentration of 5.2 mg/L. Was evaluated the whole-body cortisol level in order to measure the endocrine response to a stressful event. Were also investigated the gene expression of glucocorticoid receptor (GR), steroidogenic acute regulatory protein (StAR) and heat shock protein 70 (HSP 70). Fish exposed that have undergone a stressor event demonstrated low levels of cortisol. In addition, the fish stressed and exposed to agro-chemical showed a decreased expression of the StAR, HSP 70 and GR genes. The data indicate that exposure to methyl-parathion causes a decrease in the ability to respond appropriately to a stressor. Fish that have an inability to produce a satisfactory answer by the HHI axis are not able to make the necessary metabolic and ion adjustments for recovery the homeostasis, getting vulnerable to stress caused by aquaculture practices or environmental changes. / Compostos organofosforados como o parationato metílico são utilizados nas diversas etapas de produção para controlar pragas tanto na atividade agrícola como na aquicultura. O mecanismo de ação desse tipo de composto é a inibição da enzima acetilcolinesterase. O peixe-zebra (Danio rerio) vem sendo cada vez mais usado como modelo experimental em variados campos, como desenvolvimento, genética e pesquisa farmacológica. O parationato metílico já foi caracterizado como interruptor endócrino do eixo hipotálamo-hipófise-interrenal (HHI). Foi realizado um experimento de 96 horas de exposição de peixes adultos à substância testada, na concentração de 5,2 mg/L. Foi avaliado o nível de cortisol de corpo inteiro, visando medir a resposta endócrina a um evento estressor. Também foram investigadas a expressão dos genes do receptor de glicocorticoide (GR), da proteína regulatória de esteroidogenese aguda (StAR) e a proteína do choque térmico 70 (HSP 70). Os peixes expostos que foram submetidos a um evento estressor demonstraram baixos níveis de cortisol de corpo inteiro. Além disso, os peixes estressados e expostos ao agroquímico apresentaram uma diminuição da expressão dos genes GR, StAR e HSP 70. Os dados indicam que a exposição ao parationato metílico provoca uma diminuição da capacidade de responder adequadamente a um evento estressor. Peixes que possuem uma incapacidade em produzir uma resposta satisfatória do eixo HHI, não são capazes de realizar os ajustes iônicos e metabólicos necessários à recuperação da homeostase, ficando vulneráveis ao estresse causado pelas práticas aquícolas ou por alterações ambientais.

Introdução: A deficiência da 21-hidroxilase (21-OHD) é um frequente erro herdado do metabolismo que resulta no comprometimento da síntese do cortisol e/ou aldosterona e aumento da produção de andrógenos. A doença é caracterizada por uma diversidade fenotípica, variando desde virilização pré-natal da genitália externa de fetos femininos e pós-natal em ambos os sexos, com ou sem perda de sal, até quadros assintomáticos. Em seu tratamento é necessária reposição com glicocorticoide para se evitar a insuficiência adrenocortical e os sinais de virilização. Um fino ajuste na dose diária do glicocorticoide é essencial para se evitar sub ou supertratamento, com o objetivo de preservar o potencial de estatura final e fertilidade. Entretanto, tem sido observada maior frequência de obesidade e outras comorbidades metabólicas nestes pacientes; porém, a prevalência destas complicações ainda não é conhecida, bem como se estariam associadas à exposição ao glicocorticoide e/ou com fatores genéticos. Objetivos: avaliar a frequência de obesidade e de síndrome metabólica (SM) em pacientes com 21OHD; caracterizar a distribuição alélica dos polimorfismos dos genes do receptor de glicocorticoide (NR3C1) e da enzima 11beta-hidroxiesteróide desidrogenase tipo I (HSD11B1), e correlacionar a distribuição destes polimorfismos com a presença das complicações metabólicas. Métodos: Foram selecionados 109 pacientes (60 PS/49 VS), sendo 41 crianças e adolescentes (idade média 11,4 ± 3,9 anos) e 68 adultos (idade média 28,4 ± 9 anos) em tratamento com glicocorticoide e com adequado controle hormonal. Pacientes com a forma PS também receberam fludrocortisona. Adequado controle foi caracterizado por concentração normal de atividade plasmática de renina e de andrógenos de acordo com o sexo e idade nos últimos 2 anos. A obesidade nos adultos foi definida pelo IMC >= 30 kg/m² e em crianças e adolescentes pelo IMC acima do percentil 95. Síndrome metabólica foi definida segundo o critério do National Cholesterol Education Program em adultos e crianças. História familiar de hipertensão arterial, diabetes, dislipidemia, obesidade e/ou doença cardiovascular também foi avaliada. Foram mensuradas glicemia, lipoproteínas, triglicérides, colesterol total e insulina. Os alelos BclI, A3669G, ER22/23EK e N363S do gene NR3C1 e o alelo 4436InsA do gene HSD11B1 foram genotipados e as análises de associação com os fenótipos foram realizadas por meio dos testes Chi-quadrado, t-studant e análise de regressão. As análises de correlação foram feitas utilizando o teste de correlação de Pearson. Resultados: Obesidade foi observada em 31,7% das crianças e 23,5% dos adultos. Síndrome metabólica foi observada em 14,6% das crianças e 7,3% dos adultos. A prevalência dos componentes da SM foi maior no grupo dos obesos quando comparada a de pacientes não obesos (crianças e adultos). Não houve correlação significante entre o IMC, sexo, forma clínica da 21-OHD, duração da terapia e dose de GC. História familiar positiva para obesidade, hipertensão, dislipidemia e doença cardiovascular foi mais frequente nos pacientes obesos quando comparada a de pacientes não obesos, em adultos e crianças. Os polimorfismos BclI, A3669G e 4436InsA foram identificados em 23,2%, 9,7% e 14,6% dos alelos das crianças, respectivamente, e nos adultos em 26,4%, 9,6% e 18,4% dos alelos, respectivamente. A variante A3669G foi associada à maiores concentrações de LDL-c em crianças quando comparada aos carreadores do alelo selvagem. Os pacientes adultos carreadores do polimorfismo BclI apresentaram maior IMC, circunferência abdominal e PAS quando comparados aos carreadores do alelo selvagem. Não observamos diferenças estatisticamente significantes no perfil metabólico entre pacientes carreadores e não carreadores do polimorfismo 4436InsA (adultos e crianças). Conclusão: observamos que pacientes 21-OHD possuem maior prevalência de obesidade, e o grupo pediátrico maior prevalência de SM em relação à população de referência, sendo ambas independentes da dose de glicocorticoide e do tempo do tratamento. A presença de perfil metabólico adverso esteve associada à obesidade e à predisposição genética, tais como história familiar e variantes genéticas do receptor de glicocorticoide / Introduction: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is a common autosomal recessive disorder that leads to decreased glucocorticoid secretion, with or without mineralocorticoid deficiency, and increased androgen production. The disease is characterized by phenotypic variability, including a severe form with prenatal virilization of the external genitalia in female fetuses and postnatal virilization in both sexes, with or without salt loss. Current therapy aims to provide adequate glucocorticoid (GC) replacement and to suppress the abnormal androgen secretion; mineralocorticoid replacement aims to control the renal salt balance to avoid adrenal crisis. Nevertheless, these therapeutic goals are difficult to achieve in practice due to the complexity of replicating the physiologic cortisol circadian rhythm. Increased prevalence of obesity, insulin resistance, hypertension and adverse lipid profile have been observed among CAH patients under GC therapy; however, the extent of its prevalence and also whether it is associated with the GC dose or with genetic factors are not known. Objectives: to evaluate the obesity and metabolic syndrome (SM) frequencies in 21-OHD patients; to characterize the allelic distribution of the NR3C1 and HSD11B1 polymorphisms, and to correlate with the metabolic profile. Methods: One hundred and nine patients (60SW/49SV) were selected, 41 being children and adolescents (mean age 11.4 ± 3.9 yrs) and 68 adults (mean age 28.4 ± 9 yrs) all of whom received GC treatment and had adequate hormonal control. SW patients also received fludrocortisone. Adequate hormonal control was characterized by normal plasmatic rennin activity and androgen levels according to age and sex for at least two years. Blood fasting was used to obtain glucose, lipoproteins, triglycerides, total cholesterol and insulin levels. Obesity in the adult group was defined by BMI >= 30 kg/m², and in the young group by BMI > 95th percentile. Metabolic syndrome was defined by the NCEP ATPIII criteria. Family history of the hypertension, diabetes, dyslipidemia, obesity and/or cardiovascular disease was also evaluated. The BclI, A3669G, ER22/23EK and N363S alleles of the NR3C1 gene and 4436InsA of the HSD11B1 gene were genotyped and association analyses with phenotype were carried out with Chi-square, t-test and regression analysis. Correlation analyses were performed by Pearson correlation test. Results: obesity was observed in 31.7% of children and 23.5% of adults. SM was observed in 14.6% of young and 7.3% of adult patients. SM prevalence was higher in the obese group than the nonobese group (children and adults). There was no significant correlation between GC dose and BMI, sex, clinical form or treatment duration. Prevalence of family history of obesity, hypertension, dyslipidemia and cardiovascular disease was higher in the obese than in non-obese patients (children and adults). The BclI, A3669G and 4436InsA polymorphisms were found in 23.2%, 9.7% and 14.6% of the alleles in children, respectively and in 26.4%, 9.6% and 18.4% of the alleles in adults. The A3669G variant was associated to increased LDL-c levels in comparison with noncarriers in the young group. The BclI adult carriers presented higher BMI, abdominal circumference and systolic blood pressure in comparison with noncarriers. Statistically significant differences were not observed in the metabolic profile between carriers and non-carriers of the 4436InsA polymorphism (children and adults). Conclusion: in the present study, which analyzed the clinical and metabolic profile of 21-OHD patients, high obesity prevalence, independent of GC dose and treatment duration, was observed. Adverse metabolic profile was mainly associated with obesity and genetic predisposition, such as family history and NR3C1 polymorphisms

Les cellules béta pancréatiques synthétisent et sécrètent l’insuline, unique hormone hypoglycémiante de l’organisme. Ces cellules jouent un rôle central dans l’apparition du diabète, préserver leurs masses fonctionnelles est donc essentiel. Le récepteur GLP-1, appartenant à la classe B de la super famille des récepteurs couplés aux protéines G (RCPGs), est considéré comme une cible thérapeutique majeure dans le traitement du diabète de type 2. Via son récepteur, le GLP-1 potentialise la sécrétion d’insuline en réponse au glucose et favorise la survie des cellules beta. Les glucocorticoïdes sont des hormones du stress impliquées dans la régulation énergétique, largement utilisés en thérapeutique pour leur propriétés anti-inflammatoire, immunosuppresseur et antiallergique. Néanmoins, les glucocorticoïdes administrés en chronique sont diabétogènes en exerçant notamment des effets délétères sur les cellules beta. Nous avons caractérisé l’impact d’une exposition prolongée des cellules beta à un glucocorticoïde de synthèse (la dexaméthasone) sur les actions biologiques du glucose et du GLP-1.Nous montrons qu’une exposition prolongée des cellules beta à la dexaméthasone exerce des effets délétères en inhibant la sécrétion d’insuline en réponse au glucose et l’activation des kinases de survie ERK1/2 (Extracellular Regulated Kinases 1/2). A l’inverse, nous démontrons que l’exposition prolongée des cellules bêta à la dexaméthasone favorise le maintien du récepteur GLP-1 à la membrane plasmique, augmente le couplage du récepteur à la protéine Galpha s, ce qui se traduit par une production de second messager (AMPc) intracellulaire doublée. Malgré une diminution des effets du glucose, la sécrétion d’insuline et l’activation des kinases ERK1/2 en réponse au GLP-1 ne sont pas affectées. Cette étude révèle qu’une exposition chronique des cellules beta aux glucocorticoïdes 1) régule le trafficking du récepteur GLP-1 et favorise son maintien à la surface cellulaire, 2) hypersensibilise la signalisation du récepteur GLP-1 dépendante de la protéine Gαs , et 3) pourrait impacter les effets thérapeutiques des molécules ciblant l’activation du récepteur GLP-1. / Pancreatic beta cells synthesize and secrete insulin, the only hypoglycemic hormone in the body. These cells play a central role in the onset of diabetes. To protect the functional beta-cell mass is essential. The GLP-1 receptor, which belongs to the class B of the G protein-coupled receptor (GPCR) family, is a major therapeutic target in type 2 diabetes. Through its receptor, GLP-1 potentiates glucose-induced insulin secretion and improves the survival of pancreatic beta cells. Glucocorticoids are stress hormones implied in energetic metabolism and are widely used in therapeutics for their anti-inflammatory, immunosupressive and anti-allergic properties. Neverless, on chronic administration, glucocorticoids can induce metabolic syndrome especially due beta cell functional mass impairement. Here, we characterized the impact of a prolonged exposure of pancreatic beta cells to a synthetic glucocorticoid (dexamethasone) on biological actions of glucose and GLP-1.We show that a chronic exposure of beta cells to dexamethasone exerted deleterious effects on glucose-induced insulin secretion and ERK1/2 (Extracelllular Regulated Kinases 1/2) activation. In contrast, we observed that the glucocorticoid treatment increased GLP-1 receptor expression at the plasma membrane and improved the Galpha s protein coupling leading to an enhancement of cAMP production (2 fold increase). Despite the negative impact on glucose effects, glucocorticoids did not impair neither GLP-1-induced insulin secretion nor ERK1/2 activation. This study reveals that a glucocorticoid chronic exposure 1) regulates GLP-1 receptor trafficking and increases its expression to the plasma membrane, 2) causes supersensitization of Gαs-associated signaling, and 3) could impact on therapeutic effects of GLP-1 receptor-based drugs.

Hormônios glicocorticóides (GCs), através do receptor de glicocorticóide (GR), bloqueiam o processo de inflamação, suprimem a ativação do sistema imune e atuam como agentes inibidores do crescimento, in vitro e in vivo. GR interage com outros fatores de transcrição, como AP-1 e NF-κB. Para estudar o mecanismo de ação de GCs, utilizamos o modelo celular ST1, variante da linhagem C6 de glioma de rato, que é hiper-sensível a GCs. O tratamento hormonal induz completa reversão fenotípica tumoral-normal, bem como inibição dos níveis basal e induzido por TNF-α da atividade de ligação a DNA do fator de transcrição NF-κB. O papel de NF-κB na reversão fenotípica de células ST1, induzida por GCs, foi analisado por: (1) bloqueio da expressão da subunidade RelA de NF-κB através de construções \"antisense\"; (2) inibição da atividade NF-κB com o anti-oxidante curcumina. Após transfecção estável, foram isolados 12 clones transfectados com o vetor pOPI3-RelA(as), expressando o mRNA de RelA na orientação reversa, e 9 clones transfectados com o vetor parental pOPI3CAT. A proliferação destes clones foi analisada através de curvas de crescimento e eficiência de plaqueamento em suspensão de agarose. Não foi possível correlacionar a expressão de RelA com a proliferação celular, pois tanto os clones ST1-RelA(as) como alguns clones ST1-pOPI3CAT apresentaram menor taxa de crescimento e eficiência de plaqueamento em agarose, quando comparados com a célula parental ST1. Curcumina foi capaz de inibir a proliferação e a atividade de ligação a DNA do fator de transcrição NF-κB, indicando que este fator é importante no controle da proliferação das células ST1. A atividade de AP-1 também é modulada negativamente por GC, sugerindo que a inibição da proliferação mediada por GC em células ST1 se dá através da inibição conjunta de NF-κB e AP-1. / Glucocorticoid hormones (GC) bind to their receptor (GR), which acts as a transcription factor in the nucleus, blocking the inflammation process, suppressing activation of the immune system and acting as a growth-repressor and as anti-tumor agent both in vivo and in vitro. GR interacts with other transcription factors, such as AP-1 and NF-κB. To study the mecanism of action of GC, we have been using the ST1 cell model, a variant of the C6 glioma cell line, which is hyper-responsive to GC. Hormonal treatment leads ST1 cells to a dramatic tumoral-normal phenotypic reversion. We previously showed that GCs are able to repress both the basal and the TNF-α-induced levels of NF-κB DNA binding activity in ST1 cells. The role of NF-κB in the tumoral-normal phenotypic reversion induced by GC in ST1 cells was analysed by: (1) blocking the RelA subunit of NF-κB by expression of an antisense construct; (2) inhibition of NF-κB activity by treatment with curcumin (antioxidant). Upon stable transfection, we isolated 12 clones transfected with pOPI3-RelA(as) vector, which express reverse RelA mRNA, and 9 clones transfected with the empty pOPI3CAT vector. Cell proliferation of isolated clones was evaluated by growth curves and soft-agar assays. It was not possible to correlate RelA expression with cell proliferation since both types of clones (transfected with the pOPI3-RelA vector or with the empty vector) displayed a lower growth rate in monolayer culture, and decreased capacity to form colonies in semi-solid substrate, when compared to the non-transfected parental ST1 cell line. Curcumin was able to inhibit ST1 cell proliferation, as well NF-κB DNA-binding, indicating the importance of NF-κB in ST1 cells\' growth control. AP-1 activity is also downregulated by GC, suggesting that GC-mediated inhibition of cell proliferation in ST1 cells is results from concomitant inhibition of NF-κB and AP-1.

O objetivo deste trabalho foi estudar o processo pelo qual hormônios e fatores de crescimento controlam a proliferação celular em mamíferos. O modelo experimental utilizado foi linhagens de células estabelecidas em cultura. Os estudos centraram-se em dois tipos básicos de células: fibroblastos e células adrenais e o ataque experimental foi feito sob dois pontos de vista: bioquímico e genético. O ataque bioquímico envolveu desenvolver estudos cinéticos da síntese de DNA não só durante o carenciamento de células para soro, como também durante a reestimulação de células carenciadas por:soro, hormônios e fatores de crescimento. Medidas do conteúdo intracelular de cAMP foram efetuadas com o intuito de adquirir informações à respeito do mecanismo de ação destes fatores. Um modelo de ciclo celular foi proposto no qual o controle do crescimento seria exercido através de reguladores positivos e negativos que agiriam estimulando ou inibindo a passagem de células do estado de repouso (Go) para a fase proliferativa. Entre os reguladores positivos (estimuladores) do sistema fibroblasto, encontra-se hormônios clássicos, como esteróides e insulina, e fatores de crescimento de natureza hormonal como EGF, PF (fator proteico extraído de glândulas pituitárias) e prostaglandina F2α. O esteróide hidrocortisona pode agir como regulador negativo, inibindo o crescimento de fibroblastos. Medidas do período de tempo transcorrido desde a estimulação de células carenciadas (Go), até o aparecimento da onda de síntese de DNA (período definido operacionalmente como Gl) foram feitas. Em fibroblastos 3T3 este período foi de 12 a 13 horas tanto para células estimuladas com soro como com hormônios clássicos (hidrocortisona, insulina) ou fatores de crescimento (EGF, PF) ou ainda com combinações deles (EGF + PF + insulina; PF + hidrocortisona; PF + hidrocortisona + insulina). No sistema células adrenais, adrenocorticotropina (ACTH) foi o único hormônio clássico que apresentou atividade sobre o crescimento destas células e também o único efetuador negativo encontrado. Neste sistema PF mostrou-se como o único fator com atividade estimulatória sobre o crescimento. Gl aqui foi de 11 horas tanto para células estimuladas com soro como com PF. Além disso os hormônios clássicos hidrocortisona e insulina não apresentaram atividade estimulatória por si só ou em combinação com PF. A análise da ação de hidrocortisona no sistema fibroblasto e de ACTH no sistema células adrenais estimuladas, forneceu evidências de que após deixar Go, em direção a S, numa certa altura de Gl as células tornam-se irreversivelmente comprometidas com o processo replicativo. Este comprometimento parece ocorrer 5 horas antes de S, sendo referido como Glc. Em face destes resultados foi proposto que os reguladores agem estimulando ou inibindo a transição Go → Glc. Na tentativa de obter maior definição do sistema de controle do crescimento, aproveitamo-nos das vantagens oferecidas pelo modelo experimental usado, para a busca de mutantes do tipo regulatório. Esta busca resultou no isolamento das linhagens ST1 e AR-1, derivadas, respectivamente, de fibroblastos 3T3 e células adrenais Y-l. Entre os vários aspectos interessantes da linhagem ST1 destaca-se: a) o dramático efeito de hidrocortisona causando mudança nas características das células as quais passam de um fenótipo tipicamente transformado para normal. Este fenômeno foi observado tanto \"in vitro\" (através de medidas de parâmetros de crescimento) como \"in vivo\" (através de ensaios de tumorogenicidade); b) as alterações morfológicas de caráter antagônico provocadas, por um lado, pela adição de hidrocortisona (causando achatamento) e, por outro, pela retirada do soro ou adição de cAMP ao meio de cultura (arredondamento). Através do estudo da ação de inibidores, obteve-se evidências do envolvimento de microtúbulos nestas alterações morfológicas. A análise do conteúdo intracelular de cAMP indicou que este nucleotídeo não atua como mediador da ação de hidrocortisona. Sua ação parece ser devida à indução de alterações no sistema superfície celular - membrana -citoesqueleto. Ao contrário de outros variantes de células Y-l resistentes à ACTH, células AR-1 mostraram-se também resistentes a cAMP. A utilidade destas células nos estudos da postulada mediação deste nucleotídeo na ação de ACTH, é óbvia. / The aim of this work was to study the process by which hormones and growth factors control proliferation of mammalian cells. Cell lines established in culture were used as the experimental model. The studies were centered on two basic types of cells: fibroblasts and adrenal cells and the experimental approach was made from two viewpoints: biochemical and genetic. The biochemical approach involved kinetic studies of the DNA synthesis process not only during serum starvation but also during restimulation of serum starved cells by serum, hormones and growth factors. Intracellular cyclic AMP determinations were made in order to gain informations on the mechanism of action of these factors. A cell cycle model was proposed in which cell growth control would be exerted by positive and negative regulators that would act by stimulating or inhibiting the flow of cells from a resting state (Go) to the proliferative phase. Among the positive regulators (stimulators) found for the fibroblast system are: classical hormones, like steroids and insulin, and growth factors of homonal nature, like EGF, PF (protein factor extracted from pituitary glands) and prostaglandin F2α. The steroid hydrocortisone can also act as a negative regulator, inhibiting fibroblast growth. Measurements of the time interval between stimulation of serum starved (Go) cells and the onset of DNA synthesis (period that is operationally defined as Gl) were made. In 3T3 fibroblasts this period was 12 to 13 hours for cells stimulated not only by serum but also by classical hormones (hydrocortisone, insulin) or growth factors (EGF, PF) or even by combinations of these factors (EGF + PF + insulin; PF + hydrocortisone; PF + hydrocortisone + insulin). In the adrenal system, adrenocorticotropin (ACTH) was the only classical hormone to present activity on the growth of these cells and also the only negative regulator found. In this system PF was shown to be the only factor with growth stimulatory activity. GL was estimated as 11 hours for cells stimulated with serum or PF. Moreover hydrocortisone and insulin had no stimulatory activity \"per si\" or in combination with PF. The analysis of hydrocortisone action on the fibroblast system on one hand and of that of ACTH on the adrenal system, on the other, indicated that upon leaving Go, towards S, at a certain point in Gl, cells become irreversibly committed to the replicative process. This commitment seems to occur 5 hours before S and is referred to as Glc. In view of these data we proposed that regulators act by stimulating or inhibiting the transition Go → Glc. In an attempt to obtain a better definition of the growth control system and taking advantage of the experimental model utilized, we searched for mutants of the regulatory type. This search resulted in the isolation of the lines ST1 and AR-l from 3T3 fibroblasts and Y-l adrenal cells, respectively. Among several interesting aspects of the STl cell line, we point out: a) the dramatic effect of hydrocortisone changing the characteristics of these cells from a typically transformed phenotype to a normal pattern. This phenomenon was observed both \"in vitro\" (by measuring a number of growth parameters) and \"in vivo\" (by tumorogenicity assays). b) morphological alterations of antagonistic nature caused by hydrocortisone (flattening) on one hand, and by the removal of serum or cAMP addition to the culture medium (rounding) on the other. Evidence for the involvement of microtubules in these alterations were obtained through studies on the action of several inhibitors. Quantitative analysis of intracellular cAMP indicated that this nucleotide does not act as a mediator of hydrocortisone action. Rather, this action seems to be due to the induction of alterations on the cell surface-membrane-cytoskeleton system. Contrary to other variants of the Y-1 line which are resistant to ACTH, AR-1 cells are also resistant to cAMP. The usefulness of these cells in studies of the postulated mediation by cAMP of the ACTH action, is obvious.

RUNX1 est un facteur de transcription essentiel pour l’hématopoïèse et joue un rôle important dans la fonction immunitaire. Des mutations surviennent dans ce gène chez 5 à 13% des patients atteints de leucémie myéloïde aiguë (LMA) (RUNX1mut) et définissent un sous-groupe particulier de LMA associé à un pronostic défavorable. En conséquence, il est nécessaire de procéder à une meilleure caractérisation génétique et de concevoir des stratégies thérapeutiques plus efficaces pour ce sousgroupe particulier de LMA. Bien que la plupart des mutations trouvées dans le gène RUNX1 dans la LMA soient supposément acquises, des mutations germinales dans RUNX1 sont observées chez les patients atteints du syndrome plaquettaire familial avec prédisposition aux hémopathies malignes (RUNX1-FPD, FPD/AML). En outre, 44 % des individus atteints évoluent vers le développement d’une LMA. Suite au séquençage du transcriptome (RNA-Seq) d’échantillons de la cohorte Leucégène, nous avons montré que le dosage allélique de RUNX1 influence l’association avec des mutations coopérantes, le profil d’expression génique et la sensibilité aux médicaments dans les échantillons primaires de LMA RUNX1mut. Aussi, la validation des mutations trouvées chez RUNX1 a mené à la découverte que 30% des mutations identifiées dans notre cohorte de LMA étaient d’origine germinale, révélant une proportion plus élevée qu’attendue de cas de mutations RUNX1 familiales. Un crible chimique a, quant à lui, révélé que la plupart des échantillons RUNX1mut sont sensibles aux glucocorticoïdes (GCs) et nous avons confirmé que les GCs inhibent la prolifération des cellules de LMA et ce, via l’interaction avec le récepteur des glucocorticoïdes (Glucocorticoid Receptor, GR). De plus, nous avons observé que les échantillons contenant des mutations RUNX1 censées entraîner une faible activité résiduelle étaient plus sensibles aux GCs. Nous avons aussi observé que la co-association de certaines mutations, SRSF2mut par exemple, et les niveaux de GR contribuaient à la sensibilité aux GCs. Suite à cela, la sensibilité acquise aux GCs a été obtenue en régulant négativement l’expression de RUNX1 dans des cellules LMA humaines, ce qui a été accompagné par une régulation positive de GR. L’analyse de transcriptome induit par GC a révélé que la différenciation des cellules de LMA induite par GCs pourrait être un mécanisme en jeu dans la réponse antiproliférative associée à ces médicaments. Plus important encore, un criblage génomique fonctionnel a identifié le répresseur transcriptionnel PLZF (ZBTB16) comme un modulateur spécifique de la réponse aux GCs dans les cellules LMA sensibles et résistantes. Ces observations fournissent une caractérisation supplémentaire de la LMA RUNX1mut, soulignant l’importance de procéder à des tests germinaux pour les patients porteurs de mutations RUNX1 délétères. Nos résultats ont également identifié un nouveau rôle pour RUNX1 dans le réseau de signalisation de GR et montrent l’importance d’investiguer le repositionnement des GCs pour traiter la LMA RUNX1mut dans des modèles précliniques. Enfin, nous avons fourni des indications sur le mécanisme d’action des GCs, en montrant que PLZF s’avère un facteur important favorisant la résistance aux GCs dans la LMA. / RUNX1 is an essential transcription factor for definite hematopoiesis and plays important roles in immune function. Mutations in RUNX1 occur in 5-13% of Acute Myeloid Leukemia (AML) patients (RUNX1mut ) and are associated with adverse outcome, thus highlighting the need for better genetic characterization and for the design of efficient therapeutic strategies for this particular AML subgroup. Although most RUNX1 mutations in AML are believed to be acquired, germline RUNX1 mutations are observed in the familial platelet disorder with predisposition to hematologic malignancies (RUNX1-FPD, FPD/AML) in which about 44% of affected individuals progress to AML. By performing RNA-sequencing of the Leucegene collection, we revealed that RUNX1 allele dosage influences the association with cooperating mutations, gene expression profile, and drug sensitivity in RUNX1mut primary AML specimens. Validation of RUNX1 mutations led to the discovery that 30% of RUNX1 mutations in our AML cohort are of germline origin, indicating a greater than expected proportion of cases with familial RUNX1 mutations. Chemical screening showed that most RUNX1mut specimens are sensitive to glucocorticoids (GC) and we confirmed that GCs inhibit AML cell proliferation via interaction with the Glucocorticoid Receptor (GR). We observed that specimens harboring RUNX1 mutations expected to result in low residual RUNX1 activity were most sensitive to GCs, and that co-associating mutations, such as SRSF2mut, as well as GR levels contribute to GC-sensitivity. Accordingly, acquired GC-sensitivity was achieved by negatively regulating RUNX1 expression in human AML cells, which was accompanied by upregulation of the GR. GC-induced transcriptome analysis revealed that GC-induced differentiation of AML cells might be a mechanism at play in the antiproliferative response to these drugs. Most critically, functional genomic screening identified the transcriptional repressor PLZF (ZBTB16) as a specific modulator of the GC response in sensitive and resistant AML cells. These findings provide additional characterization of RUNX1mut AML, further stressing the importance of germline testing for patients carrying deleterious RUNX1 mutations. Our results also identified a novel role for RUNX1 in the GR signaling network and support the rationale of investigating GC repurposing for RUNX1mut AML in preclinical models. Finally, we provided insights into the mechanism of action of GCs, which positions PLZF as an important factor promoting resistance to glucocorticoids in AML.